NOI - B2B Award entitled - Developing Red Cell-Sp
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NATIONAL INSTITUTES OF HEALTH OLAO
Contract Value
Not provided
Codes & Classification
Solicitation Number
75N98027Q00017
NAICS
325411 - Medicinal and Botanical Manufacturing
Classification Code
6505
Additional Details
Documents1
The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, has issued a combined synopsis/solicitation under procurement identifier 75N98027Q00017 for the project titled "Developing Red Cell-Sp." This procurement is conducted as a Notice of Intent (NOI) for a non-competitive award, in accordance with FAR Subpart 12.6 and FAR 12.603, and is not expected to exceed the simplified acquisition threshold. The acquisition is further authorized under 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii), which allows for non-competitive awards when only one source is reasonably available due to unique expertise or prior involvement.
The purpose of this procurement is to support the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Specifically, the NIH intends to negotiate and award a purchase order to Purdue University, Purdue Institute for Drug Discovery (DRUG), located at 575 Stadium Mall Drive, West Lafayette, IN 47907. The scope of work encompasses the synthesis, scale-up, and characterization of lead SYK inhibitors, namely S1115 and S1213, which are critical for subsequent biological evaluation by NIH investigators. These activities are essential to advancing the development of targeted therapies for sickle cell disease.
The rationale for the non-competitive award is based on the continuity and specificity of the medicinal chemistry work previously performed by Dr. Philip S. Low's laboratory at Purdue University. Purdue has been the designated extramural collaborator for this project and possesses unique, project-specific knowledge and experience with the SYK inhibitor candidates. Engaging another source would necessitate duplicating prior research, resulting in delays and increased technical risk. Therefore, Purdue University is identified as the only source reasonably available to fulfill the Year 1 requirement for this project.
Key requirements and expected deliverables include:
- Synthesis of lead SYK inhibitors S1115 and S1213
- Scale-up of these compounds to quantities suitable for biological evaluation
- Comprehensive characterization of the synthesized inhibitors to ensure quality and suitability for further research
The procurement is classified under NAICS code 325411 (Medicinal and Botanical Manufacturing), with a small business size standard of 1,250 employees. However, this requirement is not set aside for small business participation. The applicable product service code is 6505, which pertains to drugs and biologicals.
The contracting entity is the NIH Office of Logistics and Acquisition Operations (OLAO), a federal office within the Department of Health and Human Services. The primary point of contact for this opportunity is Nicholas S. Capobianco, who can be reached via email at [email protected].
The solicitation document incorporates provisions and clauses effective through Federal Acquisition Circular 2026-01, dated March 13, 2026. The notice was posted on October 20, 2026, and responses are due by November 4, 2026. The opportunity remains active and is accessible via SAM.gov at https://sam.gov/opp/65e8ddf878af4f1da391b7b3898e5a2d/view.
Contractors considering this opportunity should note the non-competitive nature of the award, the requirement for specialized medicinal chemistry expertise, and the continuity of prior research as critical factors. The scope and deliverables are tightly aligned with ongoing NIH research objectives in sickle cell disease therapeutics, and the contract will remain focused on synthesis, scale-up, and characterization of specific SYK inhibitor compounds throughout its lifecycle.